Hinge Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Hinge Health (HNGE) filed a notice under Rule 144 for potential sales of Class A shares by the Jeffrey Lieberman 2012 Family Trust, a 10% stockholder. Recent sales by Insight Venture Partners funds included blocks of shares totaling millions. Raymond James & Associates is the broker. HNGE has 62.47 million Class A shares outstanding.
Insight Venture Partners plans to sell 2.5M shares of Hinge Health (HNGE) between June and August 2026, totaling $180M in gross proceeds. The sales are part of an in-kind payout.
Hinge Health (HNGE) disclosed a proposed sale of 66,967 shares, valued at $6.03M, by a 10% stockholder under Rule 144. The sale is part of an in-kind distribution from Insight entities. Additionally, Insight-affiliated funds sold millions of shares in June and August 2026.
Over the past 7 days, alphai's AI scored 3 news stories mentioning HNGE (Hinge Health, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 3 bearish.
Recent HNGE coverage spans financial news, earnings and insider activity.
In the last 30 days, HNGE insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($106K). The most active reporter was Robinson Elliott with 5 filings.
Large insider sales could increase supply and pressure the stock lower.
Significant insider sell‑off may pressure HNGE price short‑term.
The disclosed sale could increase short‑term selling pressure on HNGE.
Guidance beat and acquisition suggest strong growth, likely supporting upside; buyback expansion may boost price support.
A modest insider sale by a director may signal slight negative sentiment but the amount is small relative to total holdings.
alphai scores every news story that mentions HNGE with an AI model for sentiment and relevance, and aggregates insider trades from Hinge Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Hinge Health (HNGE) filed a notice under Rule 144 for potential sales of Class A shares by the Jeffrey Lieberman 2012 Family Trust, a 10% stockholder. Recent sales by Insight Venture Partners funds included blocks of shares totaling millions. Raymond James & Associates is the broker. HNGE has 62.47 million Class A shares outstanding.
2 min readInsight Venture Partners plans to sell 2.5M shares of Hinge Health (HNGE) between June and August 2026, totaling $180M in gross proceeds. The sales are part of an in-kind payout.
2 min readHinge Health (HNGE) disclosed a proposed sale of 66,967 shares, valued at $6.03M, by a 10% stockholder under Rule 144. The sale is part of an in-kind distribution from Insight entities. Additionally, Insight-affiliated funds sold millions of shares in June and August 2026.
1 min readHinge Health (NYSE:HNGE) raised its 2026 revenue guidance to $856M-$860M, up from $822.16M consensus. Q2 2026 revenue grew 53% YoY to $213M, with non-GAAP operating income doubling to $62M. The company announced a $105M acquisition of Cylinder Health and expanded its share repurchase program by $300M. Analysts RBC and Truist raised price targets to $110 and $112, respectively, citing strong growth and platform expansion.
3 min readLeslie Kristina M sold 1,200 shares of Hinge Health, Inc. (HNGE) at $88.23 ($0.11M total) on 2026-08-20.
1 min readHinge Health, Inc. (HNGE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 18, 2026, Hinge Health, Inc. (the “Company”) entered into an office lease agreement (the “Lease”) with 50 Beale Street LLC, a Delaware limited liability company (the “Landlord”), for approximately 119,278 rentable squ
1 min readHinge Health (HNGE) director Kristina Murphy Leslie plans to sell 1,200 shares of common stock under Rule 144, valued at $105,876, through Morgan Stanley Smith Barney LLC, with a proposed sale date of August 20, 2026. The shares were acquired as restricted stock on April 1, 2025.
1 min readHinge Health (HNGE) stock has risen 90% YTD, outperforming industry and S&P 500. Q2 revenue grew 53% YoY to $213M, with 2026 guidance raised to $856-$860M. AI and automation improved margins, while new care programs expand market reach. Analysts project 2026 EPS of $2.50 and 2027 EPS of $3.29. Growth is driven by member yield, AI efficiency, and new care offerings, but execution risks remain.
3 min readJim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.
6 min readZacks says Hinge Health (HNGE) is a Hold (Rank #3). It raised 2026 revenue guidance to $856-$860 million and non-GAAP operating income to $236-$244 million. Q2 2026 revenues rose 53% to $212.8M. The company plans a $105M Cylinder Health acquisition to expand GI care, adding $7-$8M revenue in 2026. EPS estimates for 2026 fell to $2.50.
6 min read
